Linked Life Data

18704633

Source:http://linkedlifedata.com/resource/pubmed/id/18704633

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2008-8-15
pubmed:abstractText
Pegylated liposomal doxorubicin (PLD) is the only nonplatinum agent to significantly improve survival in patients with platinum-sensitive recurrent ovarian cancer. The present study was designed to assess the efficacy and safety of PLD plus cisplatin combination therapy in these patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1341-9625
pubmed:author
pubmed:issnType
Print
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
330-4
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer.
pubmed:affiliation
Institute of Oncology, Istanbul University, Capa, Istanbul, Turkey. faruktas2002@yahoo.com
pubmed:publicationType
Journal Article